statistiche ricercatore

statistiche per SARTORE BIANCHI, ANDREA

Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3884
NA - Nord America 3516
AS - Asia 3267
SA - Sud America 109
OC - Oceania 88
AF - Africa 47
Continente sconosciuto - Info sul continente non disponibili 15
Totale 10926
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3301
CN - Cina 2478
GB - Regno Unito 2061
IT - Italia 827
CA - Canada 189
DE - Germania 177
KR - Corea 175
JP - Giappone 169
FR - Francia 99
DK - Danimarca 98
ES - Italia 90
IN - India 77
AU - Australia 75
TW - Taiwan 73
BR - Brasile 72
NL - Olanda 68
FI - Finlandia 62
HK - Hong Kong 59
SE - Svezia 54
UA - Ucraina 53
TR - Turchia 50
IR - Iran 46
CH - Svizzera 41
RO - Romania 36
RU - Federazione Russa 26
IL - Israele 24
NO - Norvegia 22
PL - Polonia 22
BE - Belgio 20
MX - Messico 20
GR - Grecia 19
PT - Portogallo 19
CZ - Repubblica Ceca 16
TH - Thailandia 16
AT - Austria 15
IE - Irlanda 15
ID - Indonesia 14
MY - Malesia 14
NZ - Nuova Zelanda 13
SG - Singapore 12
CO - Colombia 11
AR - Argentina 10
HU - Ungheria 10
JO - Giordania 10
PK - Pakistan 9
TN - Tunisia 9
DZ - Algeria 8
EG - Egitto 8
EU - Europa 8
SK - Slovacchia (Repubblica Slovacca) 8
UZ - Uzbekistan 8
PE - Perù 7
MA - Marocco 6
VN - Vietnam 6
CL - Cile 5
GN - Guinea 5
RS - Serbia 5
SA - Arabia Saudita 5
AP - ???statistics.table.value.countryCode.AP??? 4
HR - Croazia 4
MK - Macedonia 4
A1 - ???statistics.table.value.countryCode.A1??? 3
AE - Emirati Arabi Uniti 3
IM - Isola di Man 3
LB - Libano 3
SI - Slovenia 3
SY - Repubblica araba siriana 3
ZA - Sudafrica 3
AM - Armenia 2
BD - Bangladesh 2
BJ - Benin 2
CR - Costa Rica 2
CY - Cipro 2
EC - Ecuador 2
GT - Guatemala 2
IQ - Iraq 2
KE - Kenya 2
LT - Lituania 2
MT - Malta 2
PH - Filippine 2
SD - Sudan 2
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BO - Bolivia 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GI - Gibilterra 1
MO - Macao, regione amministrativa speciale della Cina 1
NG - Nigeria 1
PA - Panama 1
PR - Porto Rico 1
UY - Uruguay 1
Totale 10926
Salva come PNG Salva come JPEG
Città #
Southend 1775
Hangzhou 976
Beijing 385
Milan 384
Fairfield 360
Seattle 315
Houston 257
Redwood City 251
Wilmington 248
Woodbridge 186
Dearborn 166
Nanjing 154
Ashburn 148
Cambridge 143
Ottawa 142
Shanghai 132
Guangzhou 97
Ann Arbor 95
Jinan 66
Tokyo 62
Shenyang 54
Central District 50
Taipei 49
Changsha 45
Torino 45
Hebei 43
Nanchang 37
Wuhan 37
Seoul 31
Tianjin 29
Chengdu 25
New York 25
Zhengzhou 25
Barcelona 23
Hefei 23
Jiaxing 22
Phoenix 20
London 19
Duncan 16
Fuzhou 16
Uppsala 16
Oslo 15
Rochester 15
Taiyuan 15
Amsterdam 14
Kunming 14
Newbury Park 14
Seongnam 14
Berlin 13
Ningbo 13
Rome 13
Boston 12
Istanbul 12
Bologna 11
Jakarta 11
Lanzhou 11
Fremont 10
Madrid 10
Mountain View 10
Silver Spring 10
Manchester 9
Salt Lake City 9
Toronto 9
Xian 9
Birmingham 8
Changchun 8
Haikou 8
Lima 8
Melbourne 8
Mumbai 8
Munich 8
New Delhi 8
Singapore 8
Taizhou 8
Baltimore 7
Brooklyn 7
Burlington 7
Chongqing 7
Cluj-napoca 7
Costa Mesa 7
Montréal 7
Nijmegen 7
Oxford 7
Porth 7
San Diego 7
Seocho 7
Toulouse 7
Utrecht 7
Athens 6
Aurora 6
Belfast 6
Brookline 6
Chennai 6
Chicago 6
Cislago 6
Florence 6
Grafing 6
Harbin 6
Heidelberg 6
Madison 6
Totale 7515
Salva come PNG Salva come JPEG
Nome #
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer 1885
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets 898
Liquid biopsy for rectal cancer: a systematic review 571
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies 491
Early-onset colorectal cancer in young individuals 388
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition 285
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer 283
Third- or Later-line Therapy for Metastatic Colorectal Cancer : Reviewing Best Practice 248
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib : combined results from two phase I trials (ALKA-372-001 and STARTRK-1) 239
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer 234
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer : the 'BRAF BeCool' study 215
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer 211
Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy 211
Increased incidence of colon cancer among individuals younger than 50 years : a 17 years analysis from the cancer registry of the municipality of Milan, Italy 187
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer : a retrospective consortium analysis 153
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer 151
Challenging chemoresistant metastatic colorectal cancer: Therapeutic strategies from the clinic and from the laboratory 149
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study) 123
Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility : a Single-Institution Experience 109
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case 108
Detection of circulating tumor DNA in early- and late-stage human malignancies 106
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer 106
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 101
Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in kras-mutant metastatic colorectal cancer 91
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer 86
The right chance for temozolomide in metastatic colorectal cancer? 86
Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET) 85
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer 83
Mutation-enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced cancers 80
Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies 78
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types 77
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer 77
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib 75
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer 75
Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast 67
A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin 65
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies 62
Concurrent small cell transformation and emergence of trans-C797S and T790M mutations under sequential treatment with EGFR inhibitors in lung adenocarcinoma 61
Clonal evolution andKRAS-METcoamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer 59
Adaptive mutability of colorectal cancers in response to targeted therapies 58
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis 57
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES) : a proof-of-concept, multicentre, open-label, phase 2 trial 57
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients 56
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer 55
Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer 54
Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer 54
Bortezomib inhibits nuclear factor-κB-dependent survival and has potent in vivo activity in mesothelioma 52
Assessment of a HER2 scoring system for colorectal cancer : results from a validation study 51
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer 51
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer 50
Regorafenib in metastatic colorectal cancer 49
A molecularly annotated platform of patient- derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer 49
Standardisation of EGFR FISH in colorectal cancer: Results of an international interlaboratory reproducibility ring study 49
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer 48
TRKA expression and NTRK1 gene copy number across solid tumours 48
The genomic landscape of response to EGFR blockade in colorectal cancer 47
Acquired resistance to EGFR-targeted therapies incolorectal cancer 47
Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer 47
Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer 47
Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab 46
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study 45
Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge : Single Institution Series and Systematic Review Study 45
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients 45
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer 45
Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection : a Systematic Review and Meta-Analysis 44
The quest for improving treatment of cancer of unknown primary (CUP) through molecularly-driven treatments: a systematic review 44
Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System 43
A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits 43
Translational challenges from the 2014 Gastrointestinal Cancers Symposium : Toward a true tailored therapy through effective research 42
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to Anti-EGFR therapies in colorectal cancer 42
Rationale and clinical results of multi-target treatments in oncology 42
Cetuximab for treatment of metastatic colorectal cancer 42
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer 42
Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer 41
Regorafenib for metastatic colorectal cancer 41
EGFR FISH in colorectal cancer: what is the current reality? 41
Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer 41
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor 40
Resistance to Anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution 39
Is codon 13 KRAS mutation biologically different from codon 12 mutation 39
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab 39
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer 38
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 38
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions 38
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy 37
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer 37
Aspirin for colorectal cancer with PIK3CA mutations : the rising of the oldest targeted therapy? 36
Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer 36
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab 36
Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients 35
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer 34
Erratum: Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer 33
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies 33
Human epidermal growth factor receptor 2 as amolecular biomarker formetastatic colorectal cancer 33
Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer 32
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases : the MetaPan study 32
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer 32
Gemcitabine and Oxaliplatin in the Treatment of Patients with Immunotherapy-Resistant Advanced Renal Cell Carcinoma: Final Results of a Single-Institution Phase II Study 32
Maintenance Therapy with Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 32
Treatment sequencing in metastatic colorectal cancer 30
Totale 11270
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11855
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11855
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2015/2016105 0000 00 00 729186
2016/2017555 19504361 57 1621 94620330
2017/20181887 9810710270 69192 101197 173315278185
2018/20192546 446252231188 125164 18793 199164272225
2019/20204057 336204159298 333415 374296 560423297362
2020/20212546 371359281240 408289 236289 73000
Totale 11855
 
 
 
Powered by IRIS-about IRIS-Utilizzo dei cookie
Logo CINECA  Copyright © 2021